20:38 , Sep 21, 2018 |  BioCentury  |  Politics, Policy & Law

Filling the rebate void

HHS’s proposal to eliminate drug rebates should have the intended consequence of increasing transparency into drug pricing in the short term. But the long view is that value-based pricing or alternative co-pay agreements will do...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
06:14 , Aug 10, 2018 |  BC Week In Review  |  Company News

CVS earns less off rebates than the Street thought

CVS Health Corp. (NYSE:CVS) reported lower-than-expected contribution of retained rebates to its 2Q18 earnings and drew closer to completing its acquisition of Aetna Inc. (NYSE:AET) -- a move expected to cut its healthcare costs. CVS revealed...
22:06 , Aug 9, 2018 |  BC Extra  |  Company News

CVS earns less off rebates than the Street thought

CVS Health Corp. (NYSE:CVS) reported lower-than-expected contribution of retained rebates to its 2Q18 earnings and drew closer to completing its acquisition of Aetna Inc. (NYSE:AET) -- a move expected to cut its healthcare costs. CVS revealed...
23:06 , Jun 7, 2018 |  BC Extra  |  Company News

Management tracks: Alder, BIO

Neurology company Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) hired Robert Azelby as president and CEO, effective June 13. Azelby was EVP and chief commercial officer at Juno Therapeutics Inc., which Celgene Corp. (NASDAQ:CELG) acquired. The Biotechnology Innovation Organization...
23:17 , Apr 11, 2018 |  BC Extra  |  Politics & Policy

CVS releases prescription savings finder tool

CVS Health Corp. (NYSE:CVS) unveiled its CVS Pharmacy Rx Savings Finder, a program to reduce out-of-pocket drug costs for CVS customers. CVS said the tool allows pharmacists to quickly assess patients’ opportunities to save on prescriptions....
12:20 , Apr 3, 2018 |  BC Extra  |  Politics & Policy

CMS leaves door open to passing on Part D rebates

CMS said it is reviewing comments about a proposal to require Medicare Part D plans to return a portion of drug manufacturer rebates to consumers. The agency noted that it could enact mandatory point-of-sale drug...
22:09 , Mar 28, 2018 |  BC Extra  |  Company News

Management tracks: Editas, Allina Health | Aetna

Genome editing company Editas Medicine Inc. (NASDAQ:EDIT) named James Mullen chairman of the board of directors. He was CEO of Patheon N.V., which Thermo Fisher Scientific Inc. (NYSE:TMO) acquired. Health plan company Allina Health and Aetna...
21:34 , Mar 27, 2018 |  BC Extra  |  Politics & Policy

Aetna will pass rebates directly to consumers

HHS Secretary Alex Azar on Tuesday applauded a decision by Aetna Inc. (NYSE:AET) to pass rebates from drug manufacturers directly to its customers at the time they fill prescriptions in an effort to increase transparency...
21:44 , Mar 23, 2018 |  BioCentury  |  Strategy

Arbiter of value

The Institute for Clinical and Economic Review is rapidly becoming the closest thing the U.S. has to an HTA agency. As an independent, non-governmental body, ICER does not have the authority over reimbursement decisions accorded to...